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Table 1 Comparisons of baseline and follow-up characteristics by Aβ and WMH status
Aβ- WMH- Aβ- WMH+ Aβ +WMH- Aβ +WMH+
n = 140 n = 39 n = 63 n = 29
Baseline characteristics
Age 61.7 (8.3)B,C,D 71.3 (7.7)A,C 66.7 (7.8)A,B,D 74.1 (5.0)A,C
Female, n 94 (67)C 23 (59) 32 (51)A 16 (55)
Education in years 10.9 (3.1) 11.9 (3.3) 11.1 (3.1) 10.3 (2.9)
Hypertension, n* 43 (34) 9 (25) 15 (25) 9 (32)
Obesity, n* 15 (14) 3 (11) 4 (8) 4 (21)
Diabetes, n* 16 (21) 3 (15) 3 (7) 5 (28)
APOE-ε4 carrier, n* 33 (51)B 5 (24)A,C,D 29 (62)B 10 (56)B
Diagnosis MCI, n 70 (50)D 21 (54)D 40 (64) 22 (76)A,B
amnestic MCI (% within MCI group) 40 (57) 15 (71) 27 (68) 17 (77)
non-amnestic MCI (% within MCI group) 30 (43) 6 (29) 13 (33) 5 (23)
CSF Aβ 1–42, pg/ml 973.6 (312.0)C,D 885.0 (242.0)C,D 404.3 (102.6)A,B 419.3 (97.2)A,B
White matter hyperintensities† 0.7 (0.5)B,D 2.3 (0.4)A,C 0.8 (0.4)B,D 2.4 (0.5)A,C
Follow-up characteristics
Follow-up time 2.1 (1.5) 2.2 (1.3) 2.1 (1.2) 2.4 (1.2)
Time to progression to dementia 1.3 (0.5)B 2.0 (0.7)A 1.7 (0.7) 2.1 (1.2)
Progression to dementia, n 8 (6)B,C,D 9 (23)A 18 (29)A 11 (38)A
- AD-type dementia, n 2 (1)B,C,D 7 (18)A 18 (29)A 10 (35)A
- Vascular dementia, n 0 (0) 2 (5) 0 (0) 1 (3)
- Frontotemporal dementia, n 4 (3) 0 (0) 0 (0) 0 (0)
- Lewy Body dementia, n 1 (1) 0 (0) 0 (0) 0 (0)
- Dementia with unknown etiology, n 1 (1) 0 (0) 0 (0) 0 (0)
Results are mean (SD) for continuous variables or frequency (%). Hypertension, obesity, diabetes and APOE ε4 genotype were only available in a subgroup of the sample
Abbreviations: Aβ amyloid-beta, AD Alzheimer’s disease, APOE Apolipoprotein E, MCI mild cognitive impairment
†WMH measured by the Fazekas scale, range 0–3
Ap < 0.05 compared to Aβ- WMH-
Bp < 0.05 compared to Aβ- WMH+
Cp < 0.05 compared to Aβ +WMH-
Dp < 0.05 compared to Aβ +WMH+
Table 2 Values of neurodegenerative markers by Aβ/WMH groups
Aβ- WMH- Aβ- WMH+ Aβ +WMH- Aβ +WMH+
Neurodegeneration markers n = 140 n = 39 n = 63 n = 29
MTA score 1.2 (1.2)B,C,D 2.6 (1.6)A,D 2.1 (1.6)A,D 3.4 (1.8)A,B,C
MTA abnormal, n 62 (45)B,C,D 32 (82)A 41 (67)A,D 26 (93)A,C
P-tau, pg/ml 54.5 (27.7)C 63.2 (29.3) 77.0 (56.3)A 65.2 (38.2)
P-tau abnormal, n 53 (38)C 22 (58) 45 (71)A 15 (52)
T-tau, pg/ml 314.7 (202.0)B,C,D 438.4 (248.0)A 499.3 (413.8)A 426.2 (275.2)A
T-tau abnormal, n 36 (26)B,C,D 20 (53)A 36 (57)A 14 (48)A
Results are mean (SD) and number (%). All analyses were adjusted for study, baseline diagnosis and demographics
Abbreviations: Aβ amyloid-beta, MTA medial temporal lobe atrophy, P-tau phosphorylated tau, T-tau Total tau, WMH white matter hyperintensities
Ap < 0.05 compared to Aβ- WMH-
Bp < 0.05 compared to Aβ- WMH+.
Cp < 0.05 compared to Aβ +WMH-.
Dp < 0.05 compared to Aβ +WMH+.
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Table 3 Cognitive performance and decline by Aβ/WMH groups
Aβ- WMH- Aβ- WMH+ Aβ +WMH- Aβ +WMH+
MMSE* n 140 39 62 27
Baseline 27.79 (27.39, 28.19) 27.52 (26.83, 28.21) 27.20 (26.62, 27.78) 27.40 (26.54, 28.25)
Slope −0.01 (− 0.15, 0.12) − 0.29 (− 0.55, − 0.02) −0.22 (− 0.44, − 0.01) − 0.31 (− 0.62, 0.00)
Memory delayed recall z-score n 133 37 58 27
Baseline −0.48 (− 0.72, − 0.24)B,C,D −1.04 (− 1.48, − 0.61)A −1.04 (− 1.41, − 0.68)A −1.33 (− 1.86, − 0.80)A
Slope 0.05 (− 0.03, 0.13) 0.02 (− 0.12, 0.17) 0.02 (− 0.11, 0.14) −0.07 (− 0.24, 0.09)
Executive functioning z-score n 130 37 60 24
Baseline −0.48 (− 0.76, − 0.21) −0.41 (− 0.92, 0.09) −0.78 (− 1.18, − 0.37) −1.12 (− 1.73, − 0.50)
Slope 0.06 (− 0.02, 0.13) −0.00 (− 0.15, 0.15) −0.03 (− 0.16, 0.10) −0.04 (− 0.23, 0.15)
Results are mean (95% confidence interval). Bold slope estimates = p < 0.05. All analyses were adjusted for study. The analyses on MMSE scores were also corrected for
demographics and baseline diagnosis
Abbreviations: Aβ amyloid-beta, MMSE mini mental state examination, WMH white matter Hyperintensities
Ap < 0.05 compared to Aβ- WMH-
Bp < 0.05 compared to Aβ- WMH+.
Cp < 0.05 compared to Aβ +WMH-.
Dp < 0.05 compared to Aβ +WMH+.
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